ABI 03
Alternative Names: ABI-03Latest Information Update: 28 Jun 2024
At a glance
- Originator Avanti Biosciences
- Class Catechins; Small molecules
- Mechanism of Action Glutamate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Congenital hyperinsulinism
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Congenital-hyperinsulinism in USA
- 30 Jul 2018 Avanti Biosciences receives SBIR phase I grant from the NIDDK for the development of new therapies for hyperinsulinemia hyperammonemia syndrome (Avanti Biosciences website, November 2022)
- 30 Jul 2018 Early research in Congenital-hyperinsulinism in USA (unspecified route) (Avanti Biosciences website, November 2022)